ParkinsonCanadaV1, Main, Exploration, bibRecord, 003301

Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study

Identifieur interne : 003301 ( Main/Exploration ); précédent : 003300; suivant : 003302

Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study

Auteurs : Richard Camicioli [États-Unis, Canada] ; Eric Lea [États-Unis] ; John G. Nutt [États-Unis] ; Gary Sexton [États-Unis] ; Barry S. Oken [États-Unis]

Source :

Clinical neuropharmacology [ 0362-5664 ] ; 2001.

RBID : Pascal:01-0392182

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Méthylphénidate, Dopamine, Transporteur, Lévodopa, Antiparkinsonien, Inhibiteur, Association médicamenteuse, Interaction médicamenteuse, Homme, Dyskinésie, Traitement, Chimiothérapie, Essai pilote, Voie orale, Voie intraveineuse, Temps réaction choix, Cognition, Hémodynamique, Motricité.
Wicri :
- topic : Transporteur, Homme.

English descriptors

KwdEn :
- Antiparkinson agent, Chemotherapy, Choice reaction time, Cognition, Conveyor, Dopamine, Drug combination, Drug interaction, Dyskinesia, Hemodynamics, Human, Inhibitor, Intravenous administration, Levodopa, Methylphenidate, Motricity, Oral administration, Parkinson disease, Pilot test, Treatment.

Abstract

We determined whether methylphenidate, a dopamine transporter blocker, modifies motor, cognitive, or affective responses to L-Dopa in Parkinson's disease (PD). Five patients who reported benefit from L-Dopa/carbidopa and motor fluctuations were admitted and withdrawn from their usual antiparkinsonian medications. On 3 consecutive days in a randomized double-blinded fashion, they took 0.2 mg/kg oral methylphenidate or placebo followed 30 minutes later by a 1-hour intravenous L-Dopa (2 mg/kg per h) or placebo infusion. Vital signs, tapping, walking, dyskinesias, mood, anxiety, concentration, and arousal were monitored every 30 minutes. Cognitive testing was performed before and following the infusion. Methylphenidate combined with L-Dopa led to greater peak right-hand tapping speed than either alone. Dyskinesia severity increased most when methylphenidate and L-Dopa were co-administered. There were no differences between conditions on the Stroop test, digit ordering, simple reaction time, or covert orienting of attention validity effect, Methylphenidate alone led to improvement in choice reaction time. Change in self-assessed analogue ratings of mood, anxiety, arousal, or concentration did not differ between conditions. Methylphenidate increased the motor effects of L-Dopa with minimal effects on cognitive or affective functions, suggesting a physiologic role for the dopamine transporter in patients with PD with motor fluctuations.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000C20
to stream PascalFrancis, to step Curation: 000103
to stream PascalFrancis, to step Checkpoint: 000A80
to stream Main, to step Merge: 003787
to stream Main, to step Curation: 003301

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study</title>
<author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, Division of Neurology, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Edmonton, Alberta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lea, Eric" sort="Lea, Eric" uniqKey="Lea E" first="Eric" last="Lea">Eric Lea</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sexton, Gary" sort="Sexton, Gary" uniqKey="Sexton G" first="Gary" last="Sexton">Gary Sexton</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oken, Barry S" sort="Oken, Barry S" uniqKey="Oken B" first="Barry S." last="Oken">Barry S. Oken</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0392182</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0392182 INIST</idno>
<idno type="RBID">Pascal:01-0392182</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C20</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000103</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000A80</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000A80</idno>
<idno type="wicri:doubleKey">0362-5664:2001:Camicioli R:methylphenidate:increases:the</idno>
<idno type="wicri:Area/Main/Merge">003787</idno>
<idno type="wicri:Area/Main/Curation">003301</idno>
<idno type="wicri:Area/Main/Exploration">003301</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study</title>
<author><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine, Division of Neurology, University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Edmonton, Alberta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lea, Eric" sort="Lea, Eric" uniqKey="Lea E" first="Eric" last="Lea">Eric Lea</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sexton, Gary" sort="Sexton, Gary" uniqKey="Sexton G" first="Gary" last="Sexton">Gary Sexton</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oken, Barry S" sort="Oken, Barry S" uniqKey="Oken B" first="Barry S." last="Oken">Barry S. Oken</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health Sciences University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Choice reaction time</term>
<term>Cognition</term>
<term>Conveyor</term>
<term>Dopamine</term>
<term>Drug combination</term>
<term>Drug interaction</term>
<term>Dyskinesia</term>
<term>Hemodynamics</term>
<term>Human</term>
<term>Inhibitor</term>
<term>Intravenous administration</term>
<term>Levodopa</term>
<term>Methylphenidate</term>
<term>Motricity</term>
<term>Oral administration</term>
<term>Parkinson disease</term>
<term>Pilot test</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Méthylphénidate</term>
<term>Dopamine</term>
<term>Transporteur</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Inhibiteur</term>
<term>Association médicamenteuse</term>
<term>Interaction médicamenteuse</term>
<term>Homme</term>
<term>Dyskinésie</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Essai pilote</term>
<term>Voie orale</term>
<term>Voie intraveineuse</term>
<term>Temps réaction choix</term>
<term>Cognition</term>
<term>Hémodynamique</term>
<term>Motricité</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Transporteur</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We determined whether methylphenidate, a dopamine transporter blocker, modifies motor, cognitive, or affective responses to L-Dopa in Parkinson's disease (PD). Five patients who reported benefit from L-Dopa/carbidopa and motor fluctuations were admitted and withdrawn from their usual antiparkinsonian medications. On 3 consecutive days in a randomized double-blinded fashion, they took 0.2 mg/kg oral methylphenidate or placebo followed 30 minutes later by a 1-hour intravenous L-Dopa (2 mg/kg per h) or placebo infusion. Vital signs, tapping, walking, dyskinesias, mood, anxiety, concentration, and arousal were monitored every 30 minutes. Cognitive testing was performed before and following the infusion. Methylphenidate combined with L-Dopa led to greater peak right-hand tapping speed than either alone. Dyskinesia severity increased most when methylphenidate and L-Dopa were co-administered. There were no differences between conditions on the Stroop test, digit ordering, simple reaction time, or covert orienting of attention validity effect, Methylphenidate alone led to improvement in choice reaction time. Change in self-assessed analogue ratings of mood, anxiety, arousal, or concentration did not differ between conditions. Methylphenidate increased the motor effects of L-Dopa with minimal effects on cognitive or affective functions, suggesting a physiologic role for the dopamine transporter in patients with PD with motor fluctuations.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Oregon</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Oregon"><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name>
</region>
<name sortKey="Lea, Eric" sort="Lea, Eric" uniqKey="Lea E" first="Eric" last="Lea">Eric Lea</name>
<name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name>
<name sortKey="Oken, Barry S" sort="Oken, Barry S" uniqKey="Oken B" first="Barry S." last="Oken">Barry S. Oken</name>
<name sortKey="Sexton, Gary" sort="Sexton, Gary" uniqKey="Sexton G" first="Gary" last="Sexton">Gary Sexton</name>
</country>
<country name="Canada"><noRegion><name sortKey="Camicioli, Richard" sort="Camicioli, Richard" uniqKey="Camicioli R" first="Richard" last="Camicioli">Richard Camicioli</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003301 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003301 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:01-0392182
   |texte=   Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study

Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri